A Picardi1, A S Ferraro2, M Miranda3, F Meconi1, A Lanti2, G Adorno4, W Arcese1, P Bollero3. 1. Stem Cell Transplant Unit, Hematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy. 2. Blood Bank, Fondazione "Policlinico Tor Vergata", Rome, Italy. 3. Oral Pathology, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy. 4. Blood Bank, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Abstract
BACKGROUND: Platelet (PLT) gel has been successfully used in tissue regeneration of diabetic and surgical wounds through the releasing of growth factors such as basic fibroblast and PLT-derived growth factors. Based on this background, our previous clinical trial have assessed the feasibility and efficacy of PLT gel for the treatment of muco-cutaneous lesions related to graft versus host disease (GvHD) after allogeneic haematopoietic stem cell transplantion (HSCT). The promising results reported in a small series of 6 patients, of whom 1 with oral ulcers, represent the rationale of the present study. MATERIALS AND METHODS: The aim of this study was to verify the efficacy and safety of PLT gel for treating oral ulcers due to chronic GvHD. Allogeneic hemocomponents were used to obtain PLT gel with an automated system for the on-site preparation and application of patient (autologous) or healthy blood donor (allogeneic)-derived fibrin sealant or PLT-rich fibrin (Vivostat system, Vivostat A/S). Ten patients with multiple oral lesions related to chronic GvHD underwent allogeneic PLT gel as local therapy alone or in combination with systemic therapy in half of the cases. RESULTS: After the second PLT gel application, all patients resumed the feeding and a significant improvement of the oral pain was observed. After a median of five PLT gel applications (range, 2-15), 7 out of 10 patients showed a complete response. No side effects were documented. CONCLUSION: These data confirm that the PLT gel may be used as a safe and effective tool, alone or in combination with systemic therapy, for the treatment of mucosal lesions of mouth related to cGvHD.
BACKGROUND: Platelet (PLT) gel has been successfully used in tissue regeneration of diabetic and surgical wounds through the releasing of growth factors such as basic fibroblast and PLT-derived growth factors. Based on this background, our previous clinical trial have assessed the feasibility and efficacy of PLT gel for the treatment of muco-cutaneous lesions related to graft versus host disease (GvHD) after allogeneic haematopoietic stem cell transplantion (HSCT). The promising results reported in a small series of 6 patients, of whom 1 with oral ulcers, represent the rationale of the present study. MATERIALS AND METHODS: The aim of this study was to verify the efficacy and safety of PLT gel for treating oral ulcers due to chronic GvHD. Allogeneic hemocomponents were used to obtain PLT gel with an automated system for the on-site preparation and application of patient (autologous) or healthy blood donor (allogeneic)-derived fibrin sealant or PLT-rich fibrin (Vivostat system, Vivostat A/S). Ten patients with multiple oral lesions related to chronic GvHD underwent allogeneic PLT gel as local therapy alone or in combination with systemic therapy in half of the cases. RESULTS: After the second PLT gel application, all patients resumed the feeding and a significant improvement of the oral pain was observed. After a median of five PLT gel applications (range, 2-15), 7 out of 10 patients showed a complete response. No side effects were documented. CONCLUSION: These data confirm that the PLT gel may be used as a safe and effective tool, alone or in combination with systemic therapy, for the treatment of mucosal lesions of mouth related to cGvHD.
Authors: Mohamed L Sorror; Rainer F Storb; Brenda M Sandmaier; Richard T Maziarz; Michael A Pulsipher; Michael B Maris; Smita Bhatia; Fabiana Ostronoff; H Joachim Deeg; Karen L Syrjala; Elihu Estey; David G Maloney; Frederick R Appelbaum; Paul J Martin; Barry E Storer Journal: J Clin Oncol Date: 2014-08-25 Impact factor: 44.544
Authors: M Robin; G F Sanz; I Ionescu; B Rio; A Sirvent; M Renaud; E Carreras; N Milpied; M Mohty; Y Beguin; P Bordigoni; T de Witte; A Picardi; D Purtill; E Gluckman; N Kroger; V Rocha Journal: Leukemia Date: 2010-09-30 Impact factor: 11.528
Authors: Alessandra Picardi; William Arcese; Simona Pollichieni; Fabio Di Piazza; Ilaria Mangione; Anna Maria Gallina; Raffaella Cerretti; Laura Cudillo; Gottardo De Angelis; Andrea Mengarelli; Teresa Dentamaro; Maria Cristina Tirindelli; Anna Chierichini; Antonella Ferrari; Renato Marciano; Marco Andreani; Francesca Bonifazi; Nicoletta Sacchi Journal: Transfusion Date: 2017-06-13 Impact factor: 3.157
Authors: Effie W Petersdorf; Claudio Anasetti; Paul J Martin; Ted Gooley; Jerald Radich; Mari Malkki; Ann Woolfrey; Anajane Smith; Eric Mickelson; John A Hansen Journal: Blood Date: 2004-07-13 Impact factor: 22.113
Authors: Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz Journal: Blood Date: 2002-07-15 Impact factor: 22.113
Authors: H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas Journal: Am J Med Date: 1980-08 Impact factor: 4.965
Authors: R Iannotta; M Celentano; S Marotta; C M Pedata; C Riccardi; I Migliaccio; A Viola; S M Muggianu; C Falco; D Bovenzi; F Ferrara; A Picardi Journal: Leuk Res Rep Date: 2022-07-27